UPDATE: Mesoblast (MESO) Reports Q1 Loss of $4.07
(Updated - November 15, 2018 4:43 PM EST)
Mesoblast (NASDAQ: MESO) reported Q1 EPS of ($4.07). Revenue for the quarter came in at $11.6 million.
- Significant increase in revenues to US$11.6 million in the first quarter FY2019, compared with US$1.2 million in the first quarter FY2018
- 66% increase in commercialization revenue from royalty income on sales of TEMCELL®1 HS. Inj. for the quarter, compared with first quarter FY2018
- Reduction in operating cash outflows in first quarter FY2019 of US$0.8 million (4%) compared with first quarter FY2018
- Loss after tax increased by $12.5 million compared to the first quarter FY2018, $10.1 million of which is due to non-cash remeasurement of contingent consideration in the comparative quarter
- Pro-forma cash on September 30, 2018 was US$95.1 million including:- US$55.1 million balance sheet cash, and- US$40.0 million from Tasly Pharmaceutical Group (Tasly) received in October 2018 in relation to the strategic cardiovascular partnership in China announced in July 2018
- An additional US$50.0 million may be available under existing arrangements with Hercules Capital and NovaQuest, subject to achievement of certain milestones.
For earnings history and earnings-related data on Mesoblast (MESO) click here.